Summary & Overview
HCPCS C9360: Neonatal Bovine Collagen Dermal Substitute, per 0.5 sq cm
HCPCS Level II code C9360 identifies a native, non-denatured neonatal bovine collagen dermal substitute (Surgimend collagen matrix) billed per 0.5 square centimeters. This code matters nationally as use of biologic dermal matrices has grown in reconstructive surgery, burn care, and complex wound management, affecting hospital supply costs and payer coverage policies. The code enables itemized reporting of biologic matrix products distinct from grafts or synthetic substitutes.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for the material and where it is typically applied, together with coverage and billing considerations relevant to these major payers. The publication covers expected benchmarks for coding and claims submission practice, common modifiers associated with surgical supply billing, and policy developments that influence reimbursement and utilization management for dermal substitutes.
The content outlines the clinical role of the product in supporting dermal regeneration, typical sites of service such as hospital operating rooms and outpatient surgical centers, and practical billing information for clinicians and coding professionals. Data not provided in the input—such as associated taxonomies, specific ICD-10 indications, payer-specific payment rates, and related codes—is noted where applicable.
Billing Code Overview
HCPCS Level II code C9360 describes a dermal substitute, native, non-denatured collagen, neonatal bovine origin (Surgimend collagen matrix), per 0.5 square centimeters. The product is a biologic dermal matrix used to support soft tissue repair and dermal regeneration in surgical wounds.
Service Type: Dermal substitute / soft tissue grafting adjunct
Typical Site of Service: Hospital operating room, ambulatory surgery center, outpatient surgical clinic, or wound care center, where surgical reconstruction or grafting procedures are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient presents to a hospital outpatient wound clinic with a chronic full-thickness lower-extremity ulcer that has failed conservative therapy (off-loading, local wound care, and topical agents) for several weeks. After debridement of necrotic tissue and assessment of wound bed vascularity, the clinician elects to apply a dermal substitute product composed of native, non-denatured neonatal bovine collagen (C9360) to provide a biologic scaffold that supports cellular ingrowth and matrix remodeling.
The clinical workflow includes pre-procedure wound assessment and measurement, informed consent, sterile preparation, sharp debridement if indicated, hemostasis, and sizing of the collagen matrix to the wound. The product is cut to size and secured to the wound with sutures, staples, or adhesive dressings per manufacturer and clinician preference. Post-application care includes graft site dressing, activity modification, serial wound checks, and documentation of product units applied using C9360 billed per 0.5 cm2. Typical sites of service are hospital outpatient departments, wound care centers, outpatient surgery centers, and inpatient operating rooms when used during surgical reconstruction.
Typical patient attributes include diabetes, peripheral vascular disease, pressure-related tissue loss, traumatic soft-tissue deficits, or surgical wound breakdown where a dermal scaffold is indicated to promote healing or prepare for subsequent skin grafting or flap coverage. Multidisciplinary coordination may involve vascular surgery, plastic surgery, podiatry, or wound care nursing staff.
Coding Specifications
| Modifier | Description |
|---|